Cargando…

Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach

BACKGROUND: Diagnosis of dementia with Lewy bodies (DLB) is challenging, largely due to a lack of diagnostic tools. Cerebrospinal fluid (CSF) biomarkers have been proven useful in Alzheimer’s disease (AD) diagnosis. Here, we aimed to identify novel CSF biomarkers for DLB using a high-throughput prot...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Steenoven, Inger, Koel-Simmelink, Marleen J. A., Vergouw, Leonie J. M., Tijms, Betty M., Piersma, Sander R., Pham, Thang V., Bridel, Claire, Ferri, Gian-Luca, Cocco, Cristina, Noli, Barbara, Worley, Paul F., Xiao, Mei-Fang, Xu, Desheng, Oeckl, Patrick, Otto, Markus, van der Flier, Wiesje M., de Jong, Frank Jan, Jimenez, Connie R., Lemstra, Afina W., Teunissen, Charlotte E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301448/ https://www.ncbi.nlm.nih.gov/pubmed/32552841 http://dx.doi.org/10.1186/s13024-020-00388-2

Ejemplares similares

VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression
por: van de Beek, Marleen, et al.
Publicado: (2020)

Disease progression in dementia with Lewy bodies: A longitudinal study on clinical symptoms, quality of life and functional impairment
por: van de Beek, Marleen, et al.
Publicado: (2022)

Family History is Associated with Phenotype in Dementia with Lewy Bodies
por: Vergouw, Leonie J.M., et al.
Publicado: (2020)

Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson’s Disease Patients and Is Present within Lewy Bodies
por: Chatterjee, Madhurima, et al.
Publicado: (2020)

Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies
por: van der Lee, Sven J., et al.
Publicado: (2021)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF
por: Boiten, Walter A., et al.
Publicado: (2020)

Correction: Boiten et al. Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. Cells 2021, 10, 38
por: Boiten, Walter A., et al.
Publicado: (2022)

Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer’s Disease
por: van de Beek, Marleen, et al.
Publicado: (2019)

Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies
por: van de Beek, M., et al.
Publicado: (2020)

EEG Characteristics of Dementia With Lewy Bodies, Alzheimer’s Disease and Mixed Pathology
por: van der Zande, Jessica J., et al.
Publicado: (2018)

Optimizing cCOG, a Web‐based tool, to detect dementia with Lewy Bodies
por: van Gils, Aniek M., et al.
Publicado: (2022)

Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies
por: Rossi, Marcello, et al.
Publicado: (2021)

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
por: Bridel, Claire, et al.
Publicado: (2018)

Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results
por: van de Beek, M., et al.
Publicado: (2021)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
por: del Campo, Marta, et al.
Publicado: (2023)

Survival in memory clinic cohort is short, even in young-onset dementia
por: Rhodius-Meester, Hanneke Frederica Maria, et al.
Publicado: (2019)

Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer’s disease
por: Hok-A-Hin, Yanaika S., et al.
Publicado: (2023)

Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2018)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
por: Hok‐A‐Hin, Yanaika S., et al.
Publicado: (2023)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

Determinants of informal care time, distress, depression, and quality of life in care partners along the trajectory of Alzheimer's disease
por: Mank, Arenda, et al.
Publicado: (2023)

Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics
por: Teunissen, Charlotte E., et al.
Publicado: (2016)

Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies
por: Coomans, Emma M., et al.
Publicado: (2023)

Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease
por: Dauwan, Meenakshi, et al.
Publicado: (2016)

MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies
por: Inguanzo, Anna, et al.
Publicado: (2023)

Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
por: Thijssen, Elisabeth H., et al.
Publicado: (2022)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort
por: Kleipool, Emma E.F., et al.
Publicado: (2019)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Gray matter T1‐w/T2‐w ratios are higher in Alzheimer's disease
por: Pelkmans, Wiesje, et al.
Publicado: (2019)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Differential diagnosis of neurodegenerative diseases using structural MRI data
por: Koikkalainen, Juha, et al.
Publicado: (2016)

Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting
por: Tong, Tong, et al.
Publicado: (2017)

Lower (123)I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies
por: Joling, Merijn, et al.
Publicado: (2018)

Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition
por: Dicks, Ellen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kcfumq4luuv7pgajrc3vreb09e